Daré Bioscience Furnishes Updated Corporate Presentation via Form 8-K
Dare Bioscience, Inc.
Subscribe to track DARE
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Daré Bioscience Furnishes Updated Corporate Presentation
Company: Dare Bioscience, Inc. (DARE)
Form: 8-K | Filed: 2026-09-09
Significance: Low
Filing Summary: • Item 7.01: Regulation FD Disclosure • Exhibit 99.1: Corporate presentation dated September 9, 2026, for use in meetings with securities market participants and investors.
Key Insight: This filing represents a routine investor relations update via Form 8-K furnishing an updated corporate presentation. No insider transaction or material corporate restructuring took place.
Comprehensive Analysis
SEC Filing Analysis: Dare Bioscience, Inc. (DARE)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Daré Bioscience furnished an updated corporate presentation under Item 7.01 (Regulation FD Disclosure) for upcoming meetings with institutional investors and securities market participants.
- Market Impact: Neutral; routine investor relations disclosure with no immediate structural or financial dilution.
Company Information
| Field | Value |
|---|---|
| Company | Dare Bioscience, Inc. |
| Ticker Symbol | DARE |
| CIK | 0001401914 |
| Industry | Pharmaceutical Preparations [2834] |
Filing Details
| Field | Value |
|---|---|
| Form Type | 8-K |
| Filing Date | September 9, 2026 |
| Items Reported | Item 7.01 (Regulation FD Disclosure), Item 9.01 (Financial Statements and Exhibits) |
| Authorized Signatory | Sabrina Martucci Johnson (President & CEO) |
Financial & Materiality Context
- Market Capitalization Context: With a micro-cap valuation of ~$10M ($0.01B) and approximately 14.98 million shares outstanding, corporate presentations are routinely utilized to communicate pipeline progress to investors.
- Dilution/Transaction Impact: None. The filing contains no equity issuance, insider transaction, or financing agreement.
Market Impact Analysis
- Direction: Neutral
- Reasoning: Item 7.01 disclosures of investor presentations are informational and do not represent unexpected material business developments.
- Volume & Sentiment: Minimal to no volume impact expected; overall sentiment remains neutral.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.